Healthcare · NYSE/NASDAQ: BSX
BOSTON SCIENTIFIC CORP
Medical Devices
Market Cap $69.50B
Verdict: High
Quality Scores
Multi-Bagger
84/100
Compounder Quality
89/100
Management Credibility
92/100
Governance
92/100
Cash Flow Quality
95/100
AI Summary
Boston Scientific (BSX) has transitioned from a period of heavy integration and strategic repositioning to a high-growth medical technology powerhouse. The company demonstrates a strong recovery from the 2020 operational deficit, with revenue nearly doubling between 2020 and 2025 (pro-forma/projected). Analysis shows steady expansion in operating margins, which grew from a depressed -0.8% in 2020 to an estimated 18% by 2025. The company's focus on high-growth adjacent markets through disciplined R&D and M&A has solidified its position in cardiovascular and endoscopy segments. Asset growth…
Top Opportunities
- Robust 20% revenue growth in latest fiscal year
- Significant Operating Cash Flow (CFO) acceleration
- Diversified medical device portfolio across Cardovascular/MedSurg
Top Risks
- Vulnerability to elective procedure volume fluctuations
- Frequent litigation costs and legal settlement volatility
- Highly competitive landscape against Medtronic and Abbott
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.